Drug Profile
Research programme: anti-RANKL therapy - Schering-Plough
Alternative Names: Anti-RANKL therapy research programme - Schering-Plough; RANKL antibodies - Schering-PloughLatest Information Update: 25 Aug 2009
Price :
$50
*
At a glance
- Originator Schering-Plough
- Class Antibodies
- Mechanism of Action Bone resorption factor inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 25 Aug 2009 Discontinued - Preclinical for Osteoporosis in USA (Parenteral)
- 20 Mar 2003 Preclinical trials in Osteoporosis in USA (Parenteral)